Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Diagnosis by ACR criteria at onset

From: High-dose intravenous immunoglobulin therapy for eosinophilic granulomatosis with polyangiitis

  EGPA patients who received IVIG during initial treatment (n = 10) EGPA patients who received IVIG on relapse after remission (n = 7) P
Asthma (yes/no) 10/0 7/0 NS*
Paranasal sinusitis (yes/no) 9/1 6/1 NS*
Multiple polyneuropathy (yes/no) 10/0 7/0 NS*
Pulmonary infiltrates (yes/no) 8/2 6/1 NS*
Extravascular eosinophils (pathology) (yes/no) 10/0 7/0 NS*
Eosinophilia in peripheral blood >10% (yes/no) 10/0 7/0 NS*
ACR 5/6 (%) 30 57.1  
ACR 6/6 (%) 70 42.9  
  1. ACR, American College of Rheumatology, EGPA, eosinophilic granulomatosis with polyangiitis; IVIG, intravenous immunoglobulin; NS, not significant.
  2. All values are expressed as means ± 1 SD.
  3. Values of P < 0.05 were considered statistically significant.
  4. *: Chi-squared testing revealed no significant differences between the two groups.